GUT:α1-抗胰蛋白酶Pi * Z变异增加了肝硬化的风险

2018-10-06 MedSci MedSci原创

有研究报道,纯合α1-抗胰蛋白酶(AAT)缺乏会增加肝病患者发展为肝硬化的风险,而杂合子变异的相关性仍不清楚。因此,研究人员评估了对非酒精性脂肪性肝病(NAFLD)或酒精中毒患者的两种最相关的AAT变体('Pi * Z'和'Pi * S')的影响。

背景及目的
有研究报道,纯合α1-抗胰蛋白酶(AAT)缺乏会增加肝病患者发展为肝硬化的风险,而杂合子变异的相关性仍不清楚。因此,研究人员评估了对非酒精性脂肪性肝病(NAFLD)或酒精中毒患者的两种最相关的AAT变体('Pi * Z'和'Pi * S')的影响。

方法
研究人员分析了1184名经活检证实的NAFLD患者和2462名慢性酒精滥用患者,并构建了多中心病例对照组。研究人员对左右患者均进行了Pi * Z和Pi * S变体的基因分型分析。

结果
Pi * Z变异在13.8%的肝硬化NAFLD患者中更为常见,但仅有2.4%的患者没有肝纤维化(p <0.0001)。因此,Pi * Z变异增加了NAFLD患者发展为肝硬化的风险(OR = 7.3(95%CI 2.2至24.8))。同样地,Pi * Z变异在6.2%的酒精滥用者中出现肝硬化,但只有2.2%的酒精滥用者没有明显的肝损伤(p <0.0001)。相反,Pi * S变异与NAFLD相关的肝硬化无关,仅与酒精相关的肝硬化相关(OR = 1.47(95%CI 0.99至2.19))。

结论
Pi * Z变异是迄今为止最强的增加NAFLD中的肝硬化的危险因素,而Pi * S变异仅会稍增加酒精滥用者的肝硬化风险。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1945192, encodeId=a0bc1945192a0, content=<a href='/topic/show?id=249488e60fe' target=_blank style='color:#2F92EE;'>#蛋白酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88760, encryptionId=249488e60fe, topicName=蛋白酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Tue Jan 01 08:07:00 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342521, encodeId=f5251342521f0, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Mon Oct 08 03:07:00 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046346, encodeId=4b961046346ea, content=谢谢!最新的信息读起来就是收获大, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=guging, createdTime=Sat Oct 06 15:07:00 CST 2018, time=2018-10-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1945192, encodeId=a0bc1945192a0, content=<a href='/topic/show?id=249488e60fe' target=_blank style='color:#2F92EE;'>#蛋白酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88760, encryptionId=249488e60fe, topicName=蛋白酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Tue Jan 01 08:07:00 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342521, encodeId=f5251342521f0, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Mon Oct 08 03:07:00 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046346, encodeId=4b961046346ea, content=谢谢!最新的信息读起来就是收获大, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=guging, createdTime=Sat Oct 06 15:07:00 CST 2018, time=2018-10-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1945192, encodeId=a0bc1945192a0, content=<a href='/topic/show?id=249488e60fe' target=_blank style='color:#2F92EE;'>#蛋白酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88760, encryptionId=249488e60fe, topicName=蛋白酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Tue Jan 01 08:07:00 CST 2019, time=2019-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342521, encodeId=f5251342521f0, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Mon Oct 08 03:07:00 CST 2018, time=2018-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1046346, encodeId=4b961046346ea, content=谢谢!最新的信息读起来就是收获大, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=guging, createdTime=Sat Oct 06 15:07:00 CST 2018, time=2018-10-06, status=1, ipAttribution=)]
    2018-10-06 guging

    谢谢!最新的信息读起来就是收获大

    0